# Alzheimer’s Disease: The Past, Present, and Future of a Globally Progressive Disease

Review · Bhuvanasai Vejandla, Sarah Savani, Rohith Appalaneni, Rithik S Veeravalli, Sai Sravya Gude

- Archive id: doi:10.7759/cureus.51705
- Published: 2024-01-05
- Venue: Cureus
- DOI: https://doi.org/10.7759/cureus.51705
- PMID: 38313929
- Citations: 43
- Source URL: https://doi.org/10.7759/cureus.51705
- PDF: https://assets.cureus.com/uploads/review_article/pdf/182967/20240105-3731-3mddw9.pdf
- Provenance: openalex

## Abstract

Alzheimer's disease (AD) is a significant 21st-century public health challenge. This article delves into AD's neurodegenerative complexities, highlighting cognitive decline, memory impairment, and societal burdens. Mechanistically, protein misfolding, amyloid-beta (Aβ) pathway abnormalities, and genetic/environmental factors are discussed. The pivotal amyloid hypothesis is dissected, focusing on Aβ aggregation's role in synaptic dysfunction and neurodegeneration. The review showcases promising therapeutic strategies, including anti-amyloid antibodies and β/γ-secretase inhibitors targeting Aβ production. Notably, the FDA-approved Lecanemab signifies a breakthrough, slowing disease progression. Anti-Tau therapies' emergence is highlighted, addressing late-stage intervention. Tau aggregation blockers and anti-Tau antibodies offer potential against intracellular tau pathology. The review underscores collaborative efforts to uncover AD's secrets and pave the way for memory preservation.

_Abstract reproduced under CC-BY (publisher license, via OpenAlex)._

Topics: [Alzheimer's, Parkinson's & Neurodegeneration](https://space-kitty.com/topics/neurodegeneration)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.